Stockscreener 앱 받기
3.96
3.13%
0.12
시간 외 거래:
3.98
0.02
+0.51%
전일 마감가:
$3.84
열려 있는:
$3.82
하루 거래량:
243.85K
Relative Volume:
0.25
시가총액:
$346.25M
수익:
$32.77M
순이익/손실:
$-101.98M
주가수익비율:
-0.4121
EPS:
-9.6101
순현금흐름:
$-112.43M
1주 성능:
-4.81%
1개월 성능:
-0.50%
6개월 성능:
+109.52%
1년 성능:
-82.16%
1일 변동 폭
$3.79
$3.99
1주일 범위
$3.74
$4.21
52주 변동 폭
$1.35
$24.43
X 4 Pharmaceuticals Inc Stock (XFOR) Company Profile
명칭
X 4 Pharmaceuticals Inc
전화
857-529-8300
주소
61 NORTH BEACON STREET, BOSTON, MA
XFOR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
XFOR
X 4 Pharmaceuticals Inc
|
3.96 | 335.76M | 32.77M | -101.98M | -112.43M | -9.6101 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
X 4 Pharmaceuticals Inc Stock (XFOR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-05 | 재개 | Stifel | Buy |
| 2023-12-12 | 다운그레이드 | B. Riley Securities | Buy → Neutral |
| 2023-08-30 | 재개 | B. Riley Securities | Buy |
| 2022-12-22 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-12-12 | 개시 | Piper Sandler | Overweight |
| 2019-12-23 | 개시 | Oppenheimer | Outperform |
| 2019-12-18 | 개시 | ROTH Capital | Buy |
| 2019-12-09 | 업그레이드 | Citigroup | Neutral → Buy |
| 2019-12-05 | 개시 | B. Riley FBR | Buy |
| 2019-06-07 | 개시 | Stifel | Buy |
| 2019-06-05 | 개시 | Cowen | Outperform |
모두보기
X 4 Pharmaceuticals Inc 주식(XFOR)의 최신 뉴스
Europe reviews first nose-spray patients could use for sudden PSVT - Stock Titan
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Given Consensus Rating of "Hold" by Analysts - MarketBeat
What drives X4 Pharmaceuticals Inc 48Q0 stock priceAnalyst Upgrades & Free Powerful Profit Generation - earlytimes.in
Torrent Pharma board gives nod to Rs 12,500-crore bond issue - TradingView — Track All Markets
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Layoff Tracker: Nido Will Close Following Lead Candidate’s Disappointing Phase II Results - BioSpace
What drives X4 Pharmaceuticals Inc stock pricePrice Momentum Alerts & Free Trading Signals to Sharpen Your Edge - earlytimes.in
4,485 Shares in Madrigal Pharmaceuticals, Inc. $MDGL Bought by Calamos Advisors LLC - MarketBeat
More than 4,600 Massachusetts biotech workers lost jobs in 2025 as industry contracts - The Business Journals
Short Interest in X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Grows By 27.1% - Defense World
Vanda Pharmaceuticals Announces FDA Approval of NEREUS™ (tradipitant) for the Prevention of Vomiting Induced by Motion: A Historic Scientific Milestone in the Prevention of Motion Sickness - PR Newswire
Short Covering: Why X4 Pharmaceuticals Inc 48Q0 stock is a strong buy callJuly 2025 Analyst Calls & Risk Controlled Daily Trade Plans - moha.gov.vn
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Q4 2024 Earnings Call Transcript - MSN
Alnylam Pharmaceuticals, Inc. $ALNY Shares Bought by Cwm LLC - MarketBeat
ANI Pharmaceuticals, Inc. $ANIP Shares Sold by Rice Hall James & Associates LLC - MarketBeat
174,077 Shares in Crinetics Pharmaceuticals, Inc. $CRNX Purchased by Rice Hall James & Associates LLC - MarketBeat
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Should You Buy X4 Pharmaceuticals (XFOR) After Golden Cross? - Finviz
X4 Pharmaceuticals, Inc.'s (NASDAQ:XFOR) Shares May Have Run Too Fast Too Soon - simplywall.st
Risks To Shareholder Returns Are Elevated At These Prices For X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) - 富途牛牛
Primary Endpoint Successfully Achieved in Lexaria’s Phase 1b Study GLP-1-H24-4 - York Dispatch
IndMoney and Federal Bank Savings AccountBull Market Opportunities & Subscribe for Free Weekly Winners - Bollywood Helpline
Will X4 Pharmaceuticals Inc. (48Q0) stock boost dividends further2025 Price Targets & Long Hold Capital Preservation Plans - Улправда
Will X4 Pharmaceuticals Inc. stock continue upward momentumEarnings Trend Report & Safe Entry Trade Signal Reports - Улправда
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Thrivent Financial for Lutherans - MarketBeat
Will X4 Pharmaceuticals Inc. stock deliver long term returns2025 Price Targets & Free Community Supported Trade Ideas - Улправда
Can X4 Pharmaceuticals Inc. stock sustain institutional interestMarket Performance Report & Risk Controlled Stock Pick Alerts - Улправда
Can X4 Pharmaceuticals Inc. stock sustain market leadership2025 Biggest Moves & Advanced Swing Trade Entry Alerts - DonanımHaber
Day Trade: Can X4 Pharmaceuticals Inc. stock sustain market leadershipQuarterly Market Summary & Daily Stock Momentum Reports - DonanımHaber
Institution Moves: Can X4 Pharmaceuticals Inc. stock outperform in 2025 bull marketMarket Growth Report & Risk Managed Investment Strategies - DonanımHaber
Can X4 Pharmaceuticals Inc. stock outperform in 2025 bull marketTrade Entry Report & Capital Efficiency Focused Strategies - DonanımHaber
BioMarin to Acquire Amicus Therapeutics for $4.8 Billion, Expanding Position as a Leader in Rare Diseases, Accelerating Revenue Growth and Strengthening Financial Outlook - BioMarin Pharmaceutical
Merger Talk: Is X4 Pharmaceuticals Inc. stock supported by strong fundamentals2025 Market Trends & Reliable Price Action Trade Plans - Улправда
• Position Sizing: Never all in — always size by riskInflation Impact on Stocks & Explosive Capital Gains - Bollywood Helpline
InMed Pharmaceuticals (INM) reports senior VP employee option expiration - Stock Titan
Weekly Analysts’ Ratings Changes for X4 Pharmaceuticals (XFOR) - Defense World
Aug Opening: Will X4 Pharmaceuticals Inc. stock deliver long term returns2025 Technical Overview & Verified Chart Pattern Trade Signals - moha.gov.vn
Bain Capital Life Sciences Investors LLC Sells 16,351,925 Shares of X4 Pharmaceuticals, Inc. $XFOR - MarketBeat
X4 Pharmaceuticals, Inc. $XFOR Shares Sold by Acorn Capital Advisors LLC - MarketBeat
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Receives Consensus Recommendation of “Hold” from Brokerages - Defense World
Acadia Pharmaceuticals Announces FDA Approval of DAYBUE® STIX (trofinetide) for Oral Solution, a New Powder Formulation of Trofinetide for the Treatment of Rett Syndrome - Markets Financial Content
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
X4 PharmaSeizing Rare Opportunities, Not Acting On A Whim - RTTNews
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Does X4 Pharmaceuticals Inc (XFOR) offer a good opportunity for investors? - setenews.com
One Peninsula drugmaker to buy another for up to $820 million around drug cut by Novartis - The Business Journals
X4 Pharmaceuticals, Inc. $XFOR Shares Sold by Pale Fire Capital SE - MarketBeat
Tracking the Evolving Narrative for X4 Pharmaceuticals After Financing and Restructuring Moves - Yahoo Finance
Mirum Pharmaceuticals Enters into Definitive Agreement to Acquire Bluejay Therapeutics, Expanding Global Leadership in Rare Disease - Business Wire
Blood pressure drug recalled for possible cross-contamination - USA Today
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
X 4 Pharmaceuticals Inc (XFOR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.52%
0.07%
자본화:
|
볼륨(24시간):